SO
KYTX icon

STRS Ohio’s Kyverna Therapeutics KYTX Stock Holding History

STRS Ohio’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,100
Closed -$5.98K – 2319
2025
Q1 		$5.98K Hold
3,100
– – ﹤0.01% 1893
2024
Q4 		$11.6K Hold
3,100
– – ﹤0.01% 1842
2024
Q3 		$15.2K Hold
3,100
– – ﹤0.01% 1909
2024
Q2 		$23.3K Buy
+3,100
New +$47.4K ﹤0.01% 1887

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

STRS Ohio's KYTX Position: Q2 2025 in Review

STRS Ohio sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 3,100 shares — an estimated $5.98K sold.

STRS Ohio first reported a position in KYTX in Q2 2024 and held it in 4 quarters. The position peaked at $23.3K in Q2 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • STRS Ohio reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • STRS Ohio sold 3,100 Kyverna Therapeutics shares in Q2 2025, an estimated $5.98K.
  • STRS Ohio first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 4 quarters.
  • STRS Ohio's Kyverna Therapeutics position peaked at $23.3K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on STRS Ohio's 13F filing for Q2 2025, filed 4 Aug 2025.